Statera Biopharma (STAB) Competitors $0.0002 +0.00 (+100.00%) As of 12:50 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock STAB vs. SYRS, VRPX, SCPS, EVLO, CMRA, GNCAQ, GNCA, ARDS, AMPE, and PXMDShould you be buying Statera Biopharma stock or one of its competitors? The main competitors of Statera Biopharma include Syros Pharmaceuticals (SYRS), Virpax Pharmaceuticals (VRPX), Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Ampio Pharmaceuticals (AMPE), and PaxMedica (PXMD). These companies are all part of the "pharmaceutical products" industry. Statera Biopharma vs. Its Competitors Syros Pharmaceuticals Virpax Pharmaceuticals Scopus BioPharma Evelo Biosciences Comera Life Sciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Ampio Pharmaceuticals PaxMedica Syros Pharmaceuticals (NASDAQ:SYRS) and Statera Biopharma (NASDAQ:STAB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends. Which has higher earnings and valuation, SYRS or STAB? Statera Biopharma has lower revenue, but higher earnings than Syros Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSyros Pharmaceuticals$386K0.11-$164.57M-$3.030.00Statera BiopharmaN/AN/AN/AN/AN/A Do insiders & institutionals believe in SYRS or STAB? 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by insiders. Comparatively, 5.5% of Statera Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, SYRS or STAB? Syros Pharmaceuticals has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, Statera Biopharma has a beta of 0.06, indicating that its share price is 94% less volatile than the S&P 500. Do analysts rate SYRS or STAB? Syros Pharmaceuticals currently has a consensus price target of $1.00, indicating a potential upside of 62,400.00%. Given Syros Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Syros Pharmaceuticals is more favorable than Statera Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syros Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Statera Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is SYRS or STAB more profitable? Statera Biopharma's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Syros PharmaceuticalsN/A -3,369.56% -97.04% Statera Biopharma N/A N/A N/A Does the media favor SYRS or STAB? In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score. Company Overall Sentiment Syros Pharmaceuticals Neutral Statera Biopharma Neutral SummarySyros Pharmaceuticals beats Statera Biopharma on 6 of the 8 factors compared between the two stocks. Get Statera Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STAB vs. The Competition Export to ExcelMetricStatera BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11K$851.80M$5.76B$9.84BDividend YieldN/A4.84%3.95%4.02%P/E RatioN/A1.1531.3126.60Price / SalesN/A26.88461.30121.37Price / CashN/A19.5637.7659.36Price / BookN/A6.7310.026.67Net IncomeN/A-$4.20M$3.27B$265.59M7 Day PerformanceN/A15.29%3.17%3.42%1 Month PerformanceN/A16.58%4.34%1.09%1 Year PerformanceN/A33.25%44.11%23.85% Statera Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STABStatera BiopharmaN/A$0.00+100.0%N/A-66.7%$11KN/A0.0020Gap UpSYRSSyros Pharmaceuticals4.0547 of 5 stars$0.00-33.3%$1.00+62,400.0%-99.9%$43K$386K0.00120Positive NewsVRPXVirpax PharmaceuticalsN/A$0.01flatN/A-99.9%$14KN/A0.007SCPSScopus BioPharmaN/A$0.00flatN/A+66.7%$13KN/A0.009EVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120CMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070High Trading VolumeGNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070ARDSAridis PharmaceuticalsN/A$0.00-50.0%N/AN/A$5KN/A0.0030Gap UpAMPEAmpio PharmaceuticalsN/A$0.00flatN/A+3,695.5%$3KN/A0.0020PXMDPaxMedicaN/A$0.00flatN/A-99.9%$2KN/A0.002Gap Up Related Companies and Tools Related Companies Syros Pharmaceuticals Competitors Virpax Pharmaceuticals Competitors Scopus BioPharma Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Ampio Pharmaceuticals Competitors PaxMedica Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STAB) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Statera Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Statera Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access